← Back to Search

GenX Mentoring Program for Respiratory Virus Resistance (GenX Trial)

N/A

Waitlist Available

Led By Teresa E Seeman, Ph.D.

Research Sponsored by University of California, Los Angeles

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 10 months

Awards & highlights

GenX Trial Summary

This trial will test if a new mentoring program can help older African-American people in a low-SES urban community to resist respiratory virus infections.

Who is the study for?

This trial is for African-American men and women over 50 living in South-Central Los Angeles who can pass basic literacy and cognitive tests. They must be part of the GenX mentoring program. Those with health conditions that could worsen by joining are excluded.Check my eligibility

What is being tested?

The study is testing if the Generation Xchange (GenX) mentoring program can boost natural resistance to viral infections like RNA viruses and coronavirus in older adults from a low-SES urban community.See study design

What are the potential side effects?

Since this trial involves a community-based mentoring program rather than medication, traditional side effects are not expected; however, participation may impact daily routines or emotional well-being.

GenX Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 10 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~10 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Concentration of Type I interferon antiviral activity (bioassay International Units / mL)

Secondary outcome measures

Pro-inflammatory cytokine concentration (pg/mL)

Respiratory virus antibody concentration (WHO international units BAU/mL)

Other outcome measures

Antiviral cell prevalence

Antiviral gene regulation

Depressive symptoms

+2 more

GenX Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Immediate GenXExperimental Treatment1 Intervention

Participants immediately commence GenX program activity (intergenerational mentoring)

Group II: Delayed GenXActive Control1 Intervention

Participants engage in parallel training/educational activities, and subsequently commence GenX program activity after 3 months

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor

1,528 Previous Clinical Trials

10,276,691 Total Patients Enrolled

1 Trials studying Coronavirus Infection

5,154 Patients Enrolled for Coronavirus Infection

National Institute on Aging (NIA)NIH

1,669 Previous Clinical Trials

28,004,954 Total Patients Enrolled

Teresa E Seeman, Ph.D.Principal InvestigatorProfessor of Medicine

Media Library

GenX intergenerational mentoring program Clinical Trial Eligibility Overview. Trial Name: NCT05534425 — N/A

Coronavirus Infection Research Study Groups: Immediate GenX, Delayed GenX

Coronavirus Infection Clinical Trial 2023: GenX intergenerational mentoring program Highlights & Side Effects. Trial Name: NCT05534425 — N/A

GenX intergenerational mentoring program 2023 Treatment Timeline for Medical Study. Trial Name: NCT05534425 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there currently openings in this clinical research project?

"According to the clinicaltrials.gov website, this medical trial is not currently enrolling patients; its original posting date was September 26th 2022 and it has been edited as recently as October 31st 2022. Nevertheless, there are 6 other studies that still have open recruitment opportunities for participants."

Answered by AI

Recent research and studies

PsychoneuroendocrinologyJournal

Intergenerational Mentoring, Eudaimonic Well-being and Gene Regulation in Older Adults: A Pilot Study

Seeman, Teresa, Sharon Stein Merkin, Deena Goldwater, and Steven W. Cole. 2020. “Intergenerational Mentoring, Eudaimonic Well-being and Gene Regulation in Older Adults: A Pilot Study”. Psychoneuroendocrinology. Elsevier BV. doi:10.1016/j.psyneuen.2019.104468.

clinicaltrials.govStudy

Enhancing Innate Anti-Viral Resistance Through A Community-Based Intervention - Generation Xchange

Steve Cole, Ph.D. 2022. "Enhancing Innate Anti-Viral Resistance Through A Community-Based Intervention - Generation Xchange". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05534425.